MPI Investment Management Inc. acquired a new stake in shares of Johnson & Johnson (NYSE:JNJ) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 13,089 shares of the company’s stock, valued at approximately $1,829,000. Johnson & Johnson makes up 2.2% of MPI Investment Management Inc.’s investment portfolio, making the stock its 19th largest position.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Bank of New York Mellon Corp increased its holdings in shares of Johnson & Johnson by 0.4% during the third quarter. Bank of New York Mellon Corp now owns 36,594,054 shares of the company’s stock worth $4,757,593,000 after buying an additional 130,437 shares in the last quarter. Legal & General Group Plc increased its holdings in shares of Johnson & Johnson by 1.7% during the third quarter. Legal & General Group Plc now owns 14,513,649 shares of the company’s stock worth $1,886,872,000 after buying an additional 237,973 shares in the last quarter. Schwab Charles Investment Management Inc. increased its holdings in shares of Johnson & Johnson by 4.6% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 12,576,360 shares of the company’s stock worth $1,757,159,000 after buying an additional 551,632 shares in the last quarter. Fisher Asset Management LLC increased its holdings in shares of Johnson & Johnson by 2.8% during the fourth quarter. Fisher Asset Management LLC now owns 12,127,379 shares of the company’s stock worth $1,694,437,000 after buying an additional 329,705 shares in the last quarter. Finally, Swiss National Bank increased its holdings in shares of Johnson & Johnson by 0.4% during the third quarter. Swiss National Bank now owns 10,778,264 shares of the company’s stock worth $1,401,282,000 after buying an additional 39,800 shares in the last quarter. Institutional investors and hedge funds own 66.16% of the company’s stock.
Johnson & Johnson opened at $121.47 on Friday, according to MarketBeat.com. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.58 and a quick ratio of 1.25. The firm has a market capitalization of $327.98 billion, a P/E ratio of 16.64, a P/E/G ratio of 1.87 and a beta of 0.74. Johnson & Johnson has a twelve month low of $121.13 and a twelve month high of $148.32.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, April 17th. The company reported $2.06 EPS for the quarter, beating the Zacks’ consensus estimate of $2.00 by $0.06. The business had revenue of $20.01 billion for the quarter, compared to analysts’ expectations of $19.50 billion. Johnson & Johnson had a net margin of 1.58% and a return on equity of 30.65%. The business’s quarterly revenue was up 12.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.83 earnings per share. sell-side analysts anticipate that Johnson & Johnson will post 8.13 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 12th. Shareholders of record on Tuesday, May 29th will be given a dividend of $0.90 per share. The ex-dividend date is Friday, May 25th. This represents a $3.60 dividend on an annualized basis and a yield of 2.96%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $0.84. Johnson & Johnson’s dividend payout ratio is 46.03%.
Several research analysts have recently issued reports on the stock. Vetr downgraded shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $124.55 price target for the company. in a report on Thursday, April 5th. Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $145.00 price target for the company in a report on Wednesday, April 11th. Deutsche Bank reiterated a “buy” rating on shares of Johnson & Johnson in a report on Wednesday, April 18th. Jefferies Group set a $165.00 price target on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Monday, February 26th. Finally, Credit Suisse Group set a $154.00 price target on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Tuesday, April 17th. Six analysts have rated the stock with a sell rating, eight have given a hold rating and ten have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $142.23.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.